Multinational clinical trials involving 30 institutions including Korea and the US… Safety and efficacy evaluation
Daewoong Pharmaceutical has entered phase 2 multinational clinical trials for its new drug candidate for idiopathic pulmonary fibrosis, ‘versiporosin (DWN12088)’.
Daewoong Pharmaceutical announced on February 6 that it completed administration of the first patient for the phase 2 clinical trial of versiphorosin on January 31.
The multinational phase 2 clinical trial of versiporosin will be conducted at regarding 30 institutions in Korea and the US, including Asan Medical Center in Seoul. In 102 patients, the safety of versiphorosin and the change in forced vital capacity (FVC) improvement following 24 weeks of administration of the test drug or placebo are evaluated.
With the goal of completing the administration of the test subjects and confirming the results by 2024, Daewoong Pharmaceutical proves the excellent anti-fibrotic effect and lung function improvement results of versiphorosin confirmed in the last non-clinical efficacy test through this clinical trial. plan.
Professor Song Jin-woo (Department of Pulmonary Medicine, Seoul Asan Medical Center), who oversees the phase 2 clinical trial of versiporosin in Korea, said, “We expect this clinical trial to be of great help in the development of a new treatment that complements the shortcomings of existing treatments.” said.
Daewoong Pharmaceutical CEO Lee Chang-jae said, “We have taken an important first step by completing the first dose of the phase 2 clinical trial. We plan to focus on strengthening our new drug development capabilities to secure successful clinical results.”
© Uihyup Newspaper Unauthorized reproduction and redistribution prohibited